Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study

Hairong Xu, Zhen Huang, Yuan Li, Qing Zhang, Lin Hao, Xiaohui Niu
Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing 100035, China

ABSTRACT

Objective: Anti-angiogenic drugs are an emerging treatment option against malignant tumors. The aim of this study was to determine whether the addition of perioperative rh-endostatin to chemotherapy could improve the probability of distant metastasis-free survival (DMFS) and overall survival (OS) in patients newly diagnosed with non-metastatic conventional osteosarcoma.

Methods: This was a controlled non-randomized clinical study that included 388 patients without clinically detectable metastatic disease enrolled from January 2008 to April 2012. The control treatment group had 272 patients; 180 were male and 92, female, with a median age of 17 years. The treatment group had 58 patients; 36 were male and 22, female, with a median age of 16 years. The control group received preoperative chemotherapy followed by surgery and postoperative chemotherapy. The treatment group received 4 cycles of rh-endostatin perioperatively in addition to chemotherapy as per the control group. Patients were followed up from 6-101 months with a median follow-up period of 50.2 months.

Results: The 5-year DMFS of the control group (61%) was significantly lower than that of the rh-endostatin group (79%) ($P = 0.013$). The 5-year OS of the control group (74%) was significantly lower than that of the rh-endostatin treatment group (87%) ($P = 0.029$). No difference in adverse drug reactions was found between these 2 groups.

Conclusions: The addition of perioperative rh-endostatin to chemotherapy could significantly improve the DMFS and OS of patients with non-metastatic osteosarcoma.

KEYWORDS

Osteosarcoma; rh-endostatin; perioperative; distant metastasis; overall survival

Introduction

Conventional osteosarcoma is the most common malignant bone tumor in children and adolescents. Long-term survival of localized osteosarcoma has increased substantially from 10%–20% in the 1970s, when surgery was the sole treatment, up to 50%–70% in the 1980s and onwards. The most common survival predictors are the presence of metastases and the histological response to preoperative chemotherapy. The value of chemotherapy for the treatment of osteosarcoma is well established. The most frequently used agents against osteosarcoma include doxorubicin, cisplatin, high-dose methotrexate (HDMTX) and ifosfamide.

Recombinant human endostatin (rh-endostatin) (Endostar™), expressed and purified in Escherichia coli with an additional 9-amino acid sequence forming another his-tag structure, was approved by the State Food and Drug Administration of China in 2005 for the treatment of non-small cell lung cancer. Since anti-angiogenic drugs are directed against developing vasculature, not tumor cells, they may stabilize tumor load, rather than produce partial or complete remission. Moreover, the discontinuation of anti-angiogenic therapy may allow a tumor to resume growth. Thus, anti-angiogenic treatment alone is not suitable for patients with malignant tumors. In preclinical studies, synergistic antitumor efficacy was observed in an osteosarcoma nude mouse model with the addition of rh-endostatin to doxorubicin.

From January 2008 to April 2012 our hospital carried out a single-institution study. This was a prospective, non-randomized, controlled, doctor-initiated clinical study in patients newly diagnosed with non-metastatic conventional osteosarcoma. The primary endpoint of this study was to determine whether the addition of perioperative rh-endostatin to chemotherapy could improve the probability of distant metastasis-free survival (DMFS) and overall survival (OS) in patients newly diagnosed with non-metastatic conventional osteosarcoma.
evaluate whether the addition of rh-endostatin to doxorubicin, cisplatin, HDMTX, and ifosfamide chemotherapy would improve overall survival (OS). The secondary endpoints included whether the addition of rh-endostatin would improve distant metastasis-free survival (DMFS) and event-free survival (EFS).

Materials and methods

Patients

All enrolled patients had histologically newly diagnosed conventional osteosarcoma (pathologically high-grade). Patients had no clinically detectable metastatic disease (Enneking stage IIB5) and received no prior treatment before enrollment. Patients had to be between 6 and 65 years of age without any contraindications to chemotherapy, including those associated with peripheral blood: white blood cells ≥ 3.0 × 10^9/L, platelets ≥ 75 × 10^9/L, and hemoglobin level ≥ 95 g/L; liver function: blood bilirubin level ≤ 2.5 × normal upper limit and transaminase level ≤ 2.5 × normal upper limit; and renal function: serum creatinine level ≤ 2.0 × normal upper limit and blood urea nitrogen level ≤ 2.5 × normal upper limit. Patients were required to have a normal electrocardiogram and no untreatable cardiovascular disease or cerebrovascular disorders and should not be pregnant. Approval for this study was obtained from the institutional review board before patient enrollment. Informed consent was obtained from all patients or their guardians.

Treatments

There were 2 treatment arms, the control group (doxorubicin, cisplatin, HDMTX, and ifosfamide) and the rh-endostatin group (doxorubicin, cisplatin, HDMTX, ifosfamide, and rh-endostatin). Both treatment regimens were explained in detail to patients or their guardians. It was the patient’s/guardians’ final decision to enroll in either the control group or the rh-endostatin group. The informed consent form was completed and signed by the patient or their legal representative before the commencement of the treatment.

Both regimens called for an initial period of chemotherapy, designated as induction therapy, that lasted about 2 months, followed by definitive resection of the primary tumor. Maintenance chemotherapy was scheduled to begin 2 weeks after the surgery but did not begin until the surgeons had determined that the surgical wound was healing adequately. However, if the initial surgical plan was amputation of the affected limb the patients received no induction therapy.

The sequence of 1 cycle of chemotherapy was HDMTX, followed by ifosfamide, doxorubicin, cisplatin, and a repeated dose of HDMTX. HDMTX (10 g/m²) was administered as a 4-hour infusion followed by leucovorin rescue. Serum methotrexate levels and renal function were monitored daily and every 3 days, respectively. Hydration and alkalinization with leucovorin were specified in the event of delayed methotrexate excretion. Ifosfamide (15 g/m²) was administered with mesna protection for 5 days. Doxorubicin was administered at a dose of 90 mg/m² for 3 consecutive days, and cisplatin was administered during the first day of doxorubicin delivery at a dose of 120 mg/m². One cycle of induction chemotherapy lasted about 2 months, and 4 cycles of maintenance chemotherapy lasted about 8 months.

Rh-endostatin was administered at a dose of 15 mg for 14 consecutive days. Subsequently, the patients had a 7-day break followed by the repeated administration of rh-endostatin. We specified that the administration of rh-endostatin would be separated from the administration of methotrexate, ifosfamide, doxorubicin, and cisplatin by a minimum of 2 hours. Rh-endostatin was administered as a 4-6 hours infusion for a total of 4 cycles along with both induction and maintenance chemotherapy.

Definitive surgery was performed at week 9 for limbsalvage patients and at week 1 for amputation patients. Surgery was administered with curative intent and achieved a wide or marginal margin in all cases.

Endpoints and statistical analysis

The primary endpoint was OS, defined as the time from study entry until death or last patient contact. Patients without events were censored at the date of last contact. The secondary endpoints included DMFS, EFS, and toxicity. DMFS was defined as the time from study entry until distant metastasis or last patient contact, whichever came first. EFS was defined as the time from study entry until an adverse event or last patient contact, whichever came first. Adverse events included disease progression, the diagnosis of a second malignant neoplasm, or death before disease progression. Disease progression included local recurrence and distant metastasis. Patients without adverse events were censored at the date of last contact. Toxicity was monitored using World Health Organization common toxicity criteria10, with special attention to hepatotoxicity and nephrotoxicity. We compared the incidence of grades III and IV adverse events for the 2 groups. OS, DMFS, and EFS were estimated using
the Kaplan-Meier method. The possible risks of each factor were summarized using hazard ratios (HRs) from multivariate Cox regression models. HRs were expressed relative to patients in the baseline category of the factor of interest. An HR < 1.0 and > 1.0 indicate a lower and higher risk, respectively, of the event for patients in that category compared with the baseline category. The survival curves were drawn using Prism 7 Software. The statistical significance of the comparisons of risk for adverse events was assessed by means of the log-rank test.

The sample size was estimated as follows. Using a power of 80% and an alpha of 0.05, the 5-year survival for the control group was approximately 60%, and that of the test group was expected to be 80%. The ratio of the test group and control group was about 1:4. The total sample size was estimated to be 250 cases. However, due to the possibility that not all cases will meet the eligibility criteria and some would be lost to follow-up, the final number of cases was estimated to be 350–380.

Results

Patient characteristics

A total of 388 patients were enrolled. Among the 310 patients enrolled in the control group, 38 did not meet the eligibility criteria. Among the 78 patients enrolled in the rh-endostatin group, 20 did not meet the eligibility criteria. Finally, 330 patients were included in this study. Among them, 272 were in the control group, and 58 were in the rh-endostatin group at a ratio of 4.7:1. The control group contained 180 men and 92 women with a median age of 17 years. In the rh-endostatin group, there were 36 men and 22 women with a median age of 16 years. Follow-up ranged from 6–111 months with a mean period of 56 months. There was no statistical difference in sex, age, location of the tumor, tumor volume, surgical margin, or surgery between the 2 groups (Table 1).

Local recurrence and distant metastasis

There were 26 local recurrences in the control group with a recurrence rate of 9.6% (26/272). In the rh-endostatin group, there were 3 local recurrences with a recurrence rate of 5.2% (3/58). The number of local recurrences was not significantly different between the 2 groups ($P = 0.284$).

In the control group, 94 patients developed distant metastasis, including 74 lung metastases alone, 10 bone metastases alone, 7 bone and lung metastases, 1 lung and brain metastases, and 2 lung and abdominal metastases. The distant metastasis rate for the control group was 34.6% (94/272). In the rh-endostatin group, 12 patients developed distant metastases, including 9 lung metastases alone, 1 bone metastasis alone, and 2 bone and lung metastases. The distant metastasis rate for the rh-endostatin group was 20.7% (12/58). There was a significant difference regarding the number of distant metastases between the 2 groups ($P = 0.04$).

Distant metastasis-free survival

In the control group, the 2-year and 5-year DMFS rates were 71% and 61%, respectively. In the rh-endostatin group, the 2-year and 5-year DMFS rates were 82% and 79%, respectively. The 2 groups were significantly different regarding their DMFS rates ($P = 0.013$, log rank) (Figure 1). The relative risk of distant metastasis for patients who had
received rh-endostatin was 0.478 [95% confidence interval (CI), 0.300–0.761, \(P = 0.014\)]

Event-free survival

In the control group, the 2-year and 5-year EFS rates were 67% and 57%, respectively. In the rh-endostatin group, the 2-year and 5-year EFS rates were 81% and 75%, respectively. There was a statistically significant difference between the 2 groups (\(P = 0.010\), log rank) (Figure 2). The relative risk of events for patients who had received rh-endostatin was 0.490 (95% CI, 0.364–0.873, \(P = 0.010\)).

Overall survival

In the control group, the 2-year and 5-year OS rates were 85% and 74%, respectively. In the rh-endostatin group, the 2-year and 5-year OS rates were 96% and 87%, respectively. There was a statistically significant difference between the 2 groups (\(P = 0.029\), log rank) (Figure 3). Multivariate analyses for OS are shown in Table 2. Surgery methods (limb salvage vs. amputation) and treatment arms (with/without rh-endostatin) were both prognostic for OS. The relative risk of death for patients who underwent amputation was 2.24 (95% CI, 1.16–4.33, \(P = 0.006\)), and for patients who had received rh-endostatin, it was 0.37 (95% CI, 0.16–0.87, \(P = 0.016\)).

Toxicity of therapy

Toxicity was reported for all the patients in this study. There was no treatment-related death in either group. The most common grade III and IV adverse reactions in the control and rh-endostatin groups were leukopenia, lowered hemoglobin level, hepatic impairment, nausea, and vomiting (Table 3). No adverse cardiac toxicity was observed, and no delayed wound healing was observed in either group. There was no significant difference in adverse effects between the 2 groups. No cases of discontinuation of treatment due to adverse drug reactions were observed.

Discussion

Although osteosarcoma is the most common primary malignant bone tumor, its treatment is still one of the most challenging issues in bone tumor therapy and even the entire field of oncology\(^{12,13}\). High-dose chemotherapy using methotrexate and doxorubicin has greatly increased the OS rate of osteosarcoma since the 1970s\(^{14,15}\). Over the past 30 years, oncologists have tested numerous approaches to improve the OS of osteosarcoma patients, including increasing the intensity of chemotherapy, using various combinations of chemotherapeutic agents, and even incorporating immunotherapy. However, to date, no new treatments have significantly reduced the development of lung metastases, which currently occur in up to 30%–50% of osteosarcoma patients\(^{16,17}\). Therefore, the key to improve the survival rate of osteosarcoma is reducing the incidence of lung metastases.

In 1971, Dr. Folkman proposed the theory of tumor
angiogenesis. He pointed out that both local tumor growth and distant metastases are dependent on tumor angiogenesis. Subsequently, anti-angiogenesis became a new field of cancer treatment. Anti-angiogenesis therapy-related research has shown that there exists a balance in the body’s pro-angiogenic factors and angiogenesis. However, when the primary tumor is excised, the pro-angiogenic factors dominate, thus, contributing to the formation of distant metastases. In osteosarcoma patients, a study found that the balance of systemic angiogenic factor activity and angiogenesis inhibitory factor activity was disrupted, which was associated with the occurrence of postoperative lung metastasis. Dutour’s research demonstrated that therapy using Endo cDNA/CLP is associated with a pronounced delay in tumor growth in a human-like rat orthotopic tumor model. Endo cDNA/CLP could effectively prevent the occurrence of lung metastases in osteosarcoma. We have previously undertaken promising anti-angiogenesis research on osteosarcoma in both in vitro and in vivo models. The combination of rh-endostatin and doxorubicin produced marked synergistic antitumor activity in a mouse osteosarcoma model.

Prior to commencing the current research, many details of the study design were discussed by the authors. First, when is the appropriate time to administer anti-angiogenesis therapy? The metastatic patterns of osteosarcoma show that most lung metastases occurred 6–12 months after surgical treatment. Further research revealed that the balance of pro-angiogenic factors and inhibitors was disrupted soon after the primary osteosarcoma was removed. For this study, it was decided to administer anti-angiogenesis therapy perioperatively to prevent the imbalance of pro-angiogenic factors and inhibitors. Second, should anti-angiogenesis therapy be administered alone or in conjunction with chemotherapy? As anti-angiogenesis treatment only prevents new vascular formation, in theory, it is insufficient to destroy the tumor cells. The goal of anti-angiogenesis treatment is to normalize blood vessels to ensure that more cytotoxic drugs reach the tumor cells. This may explain why

| Characteristics | HR | 95%CI | P   |
|-----------------|----|------|-----|
| Gender          |    |      |     |
| Male            | 1  |      |     |
| Female          | 1.50 | 0.88–2.56 | 0.137 |
| Age (years)     |    |      |     |
| <10             | 1  |      |     |
| 10–20           | 1.07 | 0.35–3.27 | 0.954 |
| 21–30           | 0.96 | 0.37–2.48 |     |
| >30             | 1.16 | 0.40–3.35 |     |
| Location        |    |      |     |
| Extremity       | 1  |      |     |
| Pelvis          | 2019.48 | 0–3.94*10181 | 0.486 |
| Other           | 2845.72 | 0–5.57*10181 |     |
| Tumor volume (cm³) |    |      |     |
| <150            | 1  |      |     |
| ≥150            | 1.21 | 0.70–2.11 |     |
| Tumor margin    |    |      |     |
| Radical         | 1  |      |     |
| Wide            | 4.88 | 0.47–5.00 | 0.241 |
| Marginal        | 2.27 | 0.80–6.49 |     |
| Surgery         |    |      |     |
| Limb salvage    | 1  |      |     |
| Amputation      | 2.24 | 1.16–4.33 | 0.006 |
| Treatment arms  |    |      |     |
| The control group | 1     |      |     |
| The rh-endostatin group | 0.37 | 0.16–0.87 | 0.016 |

Table 3 The toxicity profile of the two groups

| Item                  | The control group (n = 272) | The endostatin group (n = 58) | P   |
|-----------------------|------------------------------|------------------------------|-----|
|                       | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 |       |
| Leukopenia            | 137     | 87      | 28      | 1       | 30      | 16      | 4       | 0       | 0.451 |
| lower hemoglobin      | 121     | 89      | 14      | 0       | 22      | 15      | 3       | 0       | 0.169 |
| Thrombocytopenia      | 13      | 0       | 0       | 0       | 3       | 0       | 0       | 0       | 0.900 |
| Nausea and vomiting   | 24      | 217     | 31      | 0       | 6       | 47      | 5       | 0       | 0.784 |
| Oral mucositis        | 161     | 65      | 6       | 0       | 38      | 13      | 1       | 0       | 0.774 |
| Hepatic injury        | 14      | 86      | 141     | 9       | 2       | 20      | 32      | 2       | 0.695 |
| Renal injury          | 11      | 5       | 0       | 0       | 2       | 2       | 0       | 0       | 0.755 |
anti-angiogenesis therapy alone usually results in limited good outcomes. Third, should the target patients be newly diagnosed non-metastatic or advanced? Once osteosarcoma patients have developed metastasis, it is extremely difficult to cure the patients or to improve long-time survival. The primary goal of improving OS for osteosarcoma patients is to lower the occurrence of distant metastasis at an early stage.

Although it was not possible to perform a randomized study, we attempted to minimize the differences between the groups. Previous studies have shown that age, tumor size, tumor location, and other factors are possible prognostic factors. In the current study, there was no significant difference between the 2 groups in terms of age, sex, tumor location, tumor volume, and tumor margin.

We found that the 2-year and 5-year DMFS rates were significantly improved by 11% and 18%, respectively, with the addition of anti-angiogenesis therapy. For 5-year DMFS, this represents a reduction of 46% for the 39% of patients we would normally expect to develop metastatic disease. The addition of rh-endostatin to chemotherapy resulted in an improvement in the 5-year OS rate from 74% to 87% (P = 0.016; relative risk = 0.37). We considered that the improved survival can be ascribed to the decreased occurrence of distant metastasis due to the use of rh-endostatin in addition to standard multi-drug chemotherapy. The higher risk of death in the amputation group than in the limb salvage group may reflect the fact that poor responders were more likely to undergo amputation in real clinical practice.

Regarding the safety profile, there were no more serious adverse effects in the rh-endostatin group than in the control group, consistent with previous findings for the use of other anti-angiogenic agents combined with chemotherapy in the treatment of other malignancies.

In summary, the addition of rh-endostatin in patients with newly diagnosed conventional osteosarcoma resulted in a significantly lower occurrence of distant metastases and an improved OS. The addition of rh-endostatin did not increase the rate of adverse effects. However, we do not know whether the addition of rh-endostatin could improve the OS of osteosarcoma patients with advanced disease. The limitations of this research include the non-randomized design and an imbalance in the number of patients between the 2 groups. The current research requires further laboratory and multicenter clinical investigations to evaluate the potential mechanisms and confirm the clinical value of anti-angiogenesis therapy in the treatment of osteosarcoma.

Acknowledgements

Ministry of Human Resources and Social Security of the People’s Republic of China (MOHRSS) (Grant No. 2017-199). We thank Dr. Conan Hall for his kind revising of this manuscript.

Conflicts of interest statement

No potential conflicts of interest are disclosed.

References

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-90.
2. Lewis JJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99: 112-28.
3. Bacci G, Bricoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 2001; 37: 2030-9.
4. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997; 15: 76-84.
5. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer. 2011; 47: 2431-45.
6. Wang J, Gu LJ, Fu CX, Cao Z, Chen QY. Endostar combined with chemotherapy compared with chemotherapy alone in the treatment of nonsmall lung carcinoma: A meta-analysis based on Chinese patients. Indian J Cancer. 2014; 51 Suppl 3: e106-9.
7. Wang JW, Sun Y, Liu YY, Yu QT, Zhang YP, Li K, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer. 2005; 8: 283-90.
8. Xu HR, Niu XH, Zhang Q, Hao L, Ding Y, Liu WF, et al. Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncol Lett. 2011; 2: 773-8.
9. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980: 106-20.
10. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 13-47.
11. Kaste SC, Liu T, Billups CA, Daw NC, Pratt CB, Meyer WH. Tumor size as a predictor of outcome in pediatric non-metastatic
osteosarcoma of the extremity. Pediatr Blood Cancer. 2004; 43: 723-8.

12. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. In: Jaffe N, Bruland OS, Bielack S. Pediatric and Adolescent Osteosarcoma. Boston, MA: Springer; 2009: 239-62.

13. Smeland S, Wiebe T, Bohling T, Brosjo O, Jonsson K, Alvegard TA. Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience. Acta Orthop Scand. 2004; 75: 92-8.

14. Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ, et al. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer. 1974; 33: 1151-63.

15. Rosen G, Tan C, Sanmaneechai A, Beattie EJ Jr, Marcove R, Murphy ML. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer. 1975; 35: 936-45.

16. Stephens EH, Blackmon SH, Correa AM, Roth JA, Rice DC, Hofstetter W, et al. Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. J Am Coll Surg. 2011; 212: 821-6.

17. Rasalikar DD, Chu WCW, Lee V, Paunipagar BK, Cheng FWT, Li CK. Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr Radiol. 2011; 41: 227-36.

18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 283: 1182-6.

19. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010; 13: 16-28.

20. Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002; 86: 864-9.

21. Dutour A, Monteil J, Paraf F, Charissoux JL, Kaletta C, Charissoux JL, et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther. 2005; 11: 311-9.

22. Xu HR, Tian W, Niu XY, Yuan RY, Zhang Q, Chen DF, et al. In vitro study of recombinant human endostatin in combination with adriamycin in human osteosarcoma cell OS-732. Chin J Bone Tumor Disease. 2008; 7: 129-32.

23. Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer. 1975; 32: 107-107.

24. Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T, et al. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res. 2003; 407: 159-66.

25. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175: 409-16.

26. Quan GMY, Choong PFM. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2006; 25: 707-13.

27. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987-9.

28. Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015; 62: 440-4.

29. Schuetze SM, Zhao LL, Chugh R, Thomas DG, Lucas DR, Metko G, et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer. 2012; 48: 1347-53.

30. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013; 14: 371-82.

31. Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016; 122: 868-74.

32. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106: 1154-61.

33. Li BL, Hu XL, Zhao XH, Sun HG, Zhou CY, Zhang Y. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. J Chemother. 2015; 27: 301-6.

34. An JH, Lv WL. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis. Thorac Cancer. 2018; 9: 606-12.

35. Lu S, Li L, Luo Y, Zhang L, Wu G, Chen ZW, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015; 10: 206-11.

36. Guan Y, Li AC, Xiao WW, Liu S, Chen BB, Lu TX, et al. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget. 2015; 6: 33926-34.

Cite this article as: Xu H, Huang Z, Li Y, Zhang Q, Hao L, Niu X. Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study. Cancer Biol Med. 2019; 16: 166-72. doi: 10.20892/j.issn.2095-3941.2018.0315